Parp-inhibitors in BRCA-associated pancreatic cancer

Journal of the Pancreas

Volumn 15, Issue 4, 2014, Pages 340-343

  Bhalla, Anshul ^a   Saif, Muhammad Wasif ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1; BRCA2; Drug therapy; Gemcitabine; Genes; Human; Mutation; PALB2 protein; Pancreatic neoplasms; Poly(ADP ribose) polymerases

Indexed keywords

BRCA PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 19-9 ANTIGEN; CISPLATIN; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PLATINUM; RUCAPARIB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VELIPARIB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANEMIA; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DNA DETERMINATION; DNA REPAIR; DRUG EFFICACY; FATIGUE; GENE MUTATION; GENE SEQUENCE; HUMAN; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PALB2 GENE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TUMOR GENE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); GENETICS; METABOLISM; MUTATION; PANCREATIC NEOPLASMS; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; ENZYME INHIBITORS; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84905173616     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: 10.6092/1590-8577%2F2690     Document Type: Article

References (24)

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society. 2014.
2. Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D'Adamo DR, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011; 16(10):1397-402. [PMID:21934105]
3. Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2012; 51(1):14-24. [PMID: 22162228]
4. Lucas AL, Shakya R, Lipsyc MD, Mitchel EB, Kumar S, Hwang C, Deng L, et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss ofheterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res. 2013; 19(13):3396-403 [PMID:23658460]
5. The Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 Mutation Carriers. J Natl Cancer Inst. 1999; 91(15):1310-6. [PMID:10433620].
6. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94(18):1358-65. [PMID:12237281]
7. Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, Foulkes WD, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012; 107(12):2005-9. [PMID:23099806]
8. Carden CP, Yap TA, Kaye SB. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol. 2010; 22(5):473-80. [PMID:20485165]
9. Plummer ER, Calvert H. Targeting poly (ADP-ribose) polymerase: a two armed strategy for cancer therapy. Clin Cancer Res. 2007; 13(21):6252-6. [PMID:17975135]
10. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293-301. [PMID:20200537]
11. Comen EA, Robson M. Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology (Williston Park). 2010; 24(1):55-62. [PMID:20187322]
12. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol. 2011; 4:16. [PMID:21504625]
13. Jacob DA, Bahra M, Langrehr JM, Boas-Knoop S, Stefaniak R, Davis J, Schumacher G, et al. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol. 2007; 22(5):738-48. [PMID:17444865]
14. Chen S, Wang G, Niu X, Zhao J, Tan W, Wang H, Zhao L, et al. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett. 2014; 348(1-2):20-8. [PMID:24534203]
15. Yuan K, Sun Y, Zhou T, McDonald J, Chen Y. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin Cancer Res. 2013; 19(17):4750-9. [PMID:23833311]
16. Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, et al. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 2013; 7(3):308-22. [PMID:23148997]
17. Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D'Adamo DR, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011; 16(10):1397-402. [PMID:21934105]
18. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2- associated pancreatic cancer. Anticancer Res. 2011; 31(4):1417-20. [PMID: 21508395]
19. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW et al. Olaparibmonotherapy in patients with advanced cancer and a germline BRCA1/2 mutation: An open-label phase II study. J Clin Oncol. 31, 2013; (ASCO 2013 suppl; abstr 11024).
20. Pishvaian MJ, Wang H, Zhuang T, He AR et al. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). J Clin Oncol. 31, 2013; (suppl 4; abstr 147).
21. O'Reilly EM, Lowery MA, Segal MF, Smith SC et al. Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). J Clin Oncol. 32:5s, 2014; (suppl; abstr 4023).
22. Domchek S, McWilliams RR, Hendifar AE, Shroff RA. A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation. J Clin Oncol. 32:5s, 2014; (suppl; abstr TPS4161).
23. Lowery MA, Lee A, Tobias E, Sung P et al. Evaluation of PARP inhibition as a platinum sparing strategy in Brca2-deficient pancreatic tumors. J Clin Oncol. 32, 2014; (suppl; abstr e15237).
24. Klauschen F, von Winterfeld M, Stenzinger A, Sinn BV, Budczies J, Kamphues C, Bahra M, et al. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Histopathology. 2012; 61(3):409-16. [PMID:22384823]